ANTX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ANTX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
AN2 Therapeutics has the Momentum Rank of 0.
Momentum Rank measures the strength and persistence of a stock's price movement over time, rated on a scale of 1 to 10.
For Momentum Rank, we considered the residual momentum concept that was widely studied by Blitz and his colleagues as well as by Nobel Prize laureates Fama and French. However, we did not find any significant differences in the performances of stocks with different ranks of residual momentum. Therefore, we use traditional momentum instead.
Momentum Rank is determined using the standardized momentum ratio and other momentum indicators. The standardized momentum ratio is the average of the performances from 12 months ago to 1 month ago and 6 months ago to 1 month ago, divided by the beta of the stock over the past 12 months. To calculate the momentum ratio today, we would use the average of the two performance numbers.
For momentum, we found that stock price performance does not have a monotonic correlation with the momentum ratio. The stocks with the highest momentum ratios perform worse than those at about the 70th percentile. Therefore, for the momentum rank, we ranked the stocks at about the 70th percentile of the momentum ratio as the highest at 10.
A higher score reflects strong price momentum and indicates greater potential for superior performance. Conversely, a lower score indicates that momentum is either too high or too low, and stocks tend to underperform.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
Thank you for viewing the detailed overview of AN2 Therapeutics's Momentum Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Joshua M Eizen | officer: See Remarks | 3023 MONTBRETIA WAY, SAN RAMON CA 94582 |
Lucy Day | officer: Chief Financial Officer | 2032 MIDDLEFIELD ROAD, PALO ALTO CA 94301 |
Sanjay Chanda | officer: Chief Development Officer | C/O ANACOR PHARMACEUTICALS, INC., 1020 EAST MEADOW CIRCLE, PALO ALTO CA 94303 |
Robin Shane Readnour | director | 3835 CLEGHORN AVENUE, SUITE 300, NASHVILLE TN 37215 |
Joseph S Zakrzewski | director | 509 WATERVIEW PLACE, NEW HOPE PA 18938 |
Eric Easom | director, officer: Chief Executive Officer | 171 FOREST LN., MENLO PARK CA 94025 |
Ra Capital Healthcare Fund Lp | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Adjuvant Global Health Technology Fund De, L.p. | 10 percent owner | C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017 |
Kabeer Aziz | director | 376 MANHATTAN AVENUE APT. 3, BROOKLYN NY 11211 |
Kevin Michael Krause | officer: Chief Strategy Officer | 369 27TH STREET, SAN FRANCISCO CA 94131 |
Margaret M Fitzpatrick | director | C/O VISTAGEN THERAPEUTICS, INC., 343 ALLERTON AVE., SOUTH SAN FRANCISCO CA 94080 |
Melvin K Spigelman | director | THE MEDICINES COMPANY, 8 CAMPUS DRIVE, PARSIPPANY NJ 07054 |
Ra Capital Nexus Fund Ii, L.p. | 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Adjuvant Global Health Technology Fund, L.p. | 10 percent owner | C/O ADJUVANT CAPITAL, L.P., 501 FIFTH AVENUE, SUITE 1404, NEW YORK NY 10017 |
Michael Adrian Nazak | officer: Chief Accounting Officer | 5941 OPTICAL COURT, SAN JOSE CA 95138 |
From GuruFocus
By PRNewswire • 02-24-2024
By Business Wire • 01-29-2025
By Business Wire • 02-12-2024
By Business Wire • 09-13-2023
By Business Wire • 08-10-2023
By Business Wire • 11-13-2024
By Business Wire • 10-18-2023
By PRNewswire • 02-16-2024
By Business Wire • 05-14-2024
By Business Wire • 11-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.